JDRF Statement on Sanofi Insulin Price Reductions
March 17, 2023
March 17, 2023
NEW YORK, March 17 (TNStalk) -- JDRF, a non-profit dedicated to funding type 1 diabetes research, issued the following agency statement on March 16, 2023:
Sanofi announced a series of changes that will make their insulins more affordable for people living with diabetes. This includes a reduction in the list price of Lantus (insulin glargine) and the establishment of a $35 monthly cap for individuals with commercial insurance. These changes are in addition to steps taken in June 2022 . . .
Sanofi announced a series of changes that will make their insulins more affordable for people living with diabetes. This includes a reduction in the list price of Lantus (insulin glargine) and the establishment of a $35 monthly cap for individuals with commercial insurance. These changes are in addition to steps taken in June 2022 . . .